FDA Panel OKs 6 Peptides: What Patients Should Know First

On July 23–24, 2026, a federal advisory panel voted to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the FDA’s compounding list, officially the 503A Bulks List, the list of bulk substances compounding pharmacies may legally use (WVLT, Aug 6, 2026, AJMC, Jul 31, 2026), while a seventh, emideltide (DSIP), was rejected.

That vote is easy to overread: it is not FDA approval and not a safety verdict. But it is the clearest regulatory signal yet on a class of injections widely promoted for weight loss, muscle growth, injury recovery, and general health (WVLT, Aug 6, 2026). Here is what patients should know first.

What the FDA Panel Decided

The Pharmacy Compounding Advisory Committee (PCAC) met at the FDA’s White Oak campus on July 23–24, 2026, to review seven unapproved peptides for the 503A Bulks List (FDA meeting calendar) — and recommended six of them over the objections of FDA career scientists, who opposed all seven (AJMC, Jul 31, 2026).

Three limits matter. The recommendation is nonbinding — the final decision rests with the FDA and HHS (WVLT, Aug 6, 2026) — and formal rulemaking can take up to a year. Nor would a list spot mean the FDA declared these peptides safe or effective: compounded products skip standard post-market side-effect tracking and safety labeling (AJMC, Jul 31, 2026).

The Six Peptides Recommended for the Compounding List

The six were BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — none FDA-approved for any indication (AJMC, Jul 31, 2026). BPC-157, KPV, and TB-500 each passed 8–6 with one abstention; MOTS-c passed 7–5 with two abstentions; Semax and Epitalon cleared by similarly tight margins (AJMC, Jul 31, 2026, RAPS, Jul 24, 2026).

BPC-157: the most promoted, the least studied

BPC-157 is the peptide patients ask about most, promoted for injury recovery, gut health, and joint pain. The FDA’s evaluation found no evidence of effectiveness for ulcerative colitis, cited FAERS adverse events — injection site reaction, shortness of breath, diffuse hyperpigmentation, and gingival darkening — and flagged immunogenicity risk for injection or nasal use (FDA evaluation of BPC-157, RAPS, Jul 24, 2026). BPC-157 and TB-500 are doping-classified by international sports authorities and still sold online under “research use only” disclaimers despite the FDA’s 2023 restrictions (AJMC, Jul 31, 2026).

Why Emideltide (DSIP) Was Rejected

Emideltide, also called delta sleep-inducing peptide (DSIP), was the only rejection, on a 6–7 vote with one abstention (AJMC, Jul 31, 2026, RAPS, Jul 24, 2026). Its evidence base was unusually thin: a single narcolepsy case report and two small, uncontrolled opioid-withdrawal studies (ABC News, Jul 24, 2026).

There was also a route mismatch: it was proposed as an under-the-skin injection, but the existing studies used an intravenous route (ABC News, Jul 24, 2026). In the FDA’s words, “there is a lack of safety and efficacy data to support using emideltide for treating insomnia, narcolepsy and opioid use disorder” (RAPS, Jul 24, 2026).

What This Means for Compounding Pharmacies

The 503A Bulks List governs which bulk substances compounding pharmacies may legally prepare. The vote moves six compounds a step closer to that list — but nothing is legal yet. The FDA must first decide whether to accept the recommendation, then complete notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule (AJMC, Jul 31, 2026). Alliance for Pharmacy Compounding CEO Scott Brunner said the FDA must formally adopt the recommendation before compounding can begin (AJMC, Jul 31, 2026).

For patients: the pharmacy compounding today is not operating under this vote — 503A pharmacies remain bound by the FDA’s 2023 restrictions, and a prescription is required (AJMC, Jul 31, 2026, FDA briefing document). Some panel members voted yes as harm reduction against the unregulated online market. “I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist,” said committee member David Pope (AP via PBS NewsHour, Jul 23, 2026). The reconstituted panel also drew conflict-of-interest scrutiny for adding members involved in prescribing, producing, or promoting peptides (AJMC, Jul 31, 2026).

Doctor-Reported Safety Concerns

Valley endocrinologist Dr. Harmeet Narula told WVLT that “more human data is needed to show the injections are both safe and effective” (WVLT, Aug 6, 2026). See Do doctors recommend peptides?. FDA staff scientists opposed all seven, citing a lack of solid clinical trial data, inconsistent recipes from batch to batch, and the risk of harmful immune reactions (ABC News, Jul 24, 2026, AJMC, Jul 31, 2026).

“This is really alarming” — that is how Rita Jew, PharmD, president of the Institute for Safe Medication Practices, described the situation: “There aren’t that many other substances people are injecting into themselves where you see that the clinical evidence is so lacking” (AP via PBS NewsHour, Jul 23, 2026). Committee member William Zamboni, PharmD, PhD, summed up the data: “There are too many unknowns about this product” (RAPS, Jul 24, 2026).

Questions to Ask Before Considering Peptide Injections

• Is this peptide FDA-approved? No. None of the seven is approved for any indication (AJMC, Jul 31, 2026).
• What human evidence supports it? For BPC-157, the FDA found no effectiveness data and proposed not adding it to the list (FDA evaluation of BPC-157).
• Who is compounding it? Ask whether the pharmacy is 503A-licensed and vetted, and run our compounding pharmacy checklist — most of these products are still sold on the gray market (AJMC, Jul 31, 2026).
• What adverse events have been reported? Check FAERS and ask what your provider would track — compounded products have no standard post-market reporting (FDA evaluation of BPC-157, AJMC, Jul 31, 2026).
• What is the legal status today? Nothing has changed: compounding remains restricted until the FDA accepts the recommendation and completes rulemaking (AJMC, Jul 31, 2026).

The same demand pressure behind telehealth brands pivoting into peptides is why this vote matters — and why patients should treat it as the start of a regulatory timeline, not a green light. If you’re considering a peptide injection, the free 10-point pharmacy checklist and the Pharmacy & Provider Directory are good places to start.

FAQ

Are these peptides FDA-approved now?

No. The advisory vote is nonbinding; none of the seven is FDA-approved, and the FDA and HHS make the final call (AJMC, Jul 31, 2026, WVLT, Aug 6, 2026).

Can I get BPC-157 from a compounding pharmacy now?

Not yet. Compounding stays restricted until the FDA accepts the recommendation and completes rulemaking — proposed rule, comment period, final rule (AJMC, Jul 31, 2026).

What happened to emideltide (DSIP)?

It was the only rejection, 6–7 with one abstention, after the committee weighed a single narcolepsy case report and two small, uncontrolled opioid-withdrawal studies (AJMC, Jul 31, 2026, ABC News, Jul 24, 2026).

This article is for informational purposes only and is not medical advice. The panel vote was nonbinding; final decisions rest with the FDA and HHS, and no peptide is approved. Primary sources: WVLT and AJMC, corroborated by RAPS, ABC News, AP/PBS NewsHour, and FDA documents. Current as of August 29, 2026.